E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

CONCLUSION: The combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer.PMID:34357781 | DOI:10.1200/JCO.21.00944

Source: Clinical Genitourinary Cancer - August 6, 2021 Category: Cancer & Oncology Authors: Roisin M Connolly Fengmin Zhao Kathy D Miller Min-Jung Lee Richard L Piekarz Karen L Smith Ursa A Brown-Glaberman Jennifer S Winn Bryan A Faller Adedayo A Onitilo Mark E Burkard George T Budd Ellis G Levine Melanie E Royce Peter A Kaufman Alexandra Thomas Source Type: research